Compare AbbVie Inc (ABBV) vs MobilEye Global Inc (MBLY) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Mobileye (MBLY) trades at $10.00, up 4.49% today, with a bullish technical signal from moving averages and strong analyst support. The stock shows negative profitability with a net income margin of -203.97% in 2026 but maintains solid revenue growth, reaching $2.0B. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it against competitors like Waymo and Tesla.

The outlook is cautiously optimistic due to the robotaxi initiative's potential, but high execution risks and persistent losses pose challenges. Analysts project a consensus price target of $10.36, with 57.69% recommending Buy. Investors should weigh the growth opportunity against the company's current unprofitability and competitive pressures in the autonomous vehicle sector.